本文报道了口服乐腹康胶囊活菌制剂对正常人体肠道的双歧杆菌、乳杆菌、大肠杆菌等的影响。结果显示口服后，对肠道菌群有短暂（１～２天）抑制生长作用，而后对厌氧菌中的双歧杆菌、乳杆菌有明显促进生长的作用。双歧杆菌在服药前平均为５０６±１０３亿／克，服药后１０天升至１８７３±１４３亿／克，增长３７０倍（Ｐ＜００５），有显著性差异。乳杆菌服药前平均数为２７４±０２５亿／克，服药后１０天升至５０７±１２１亿／克，增长１８５倍。而对需氧的大肠杆菌和其他肠道球菌有持续的抑制作用，大肠杆菌服药前平均数为３４２±０２１亿／克，服药后１０天降至１０５±００９亿／克，仅为原来的３０％（Ｐ＜００５），有显著的差异 This article reports the effects of oral Levukang capsule viable bacteria on bifidobacteria, lactobacilli and Escherichia coli in normal human intestinal tract. The results showed that after oral administration, intestinal flora temporarily (1-2 days) inhibit growth, and then the anaerobic bacteria Bifidobacterium, Lactobacilli significantly promote growth. Bifidobacterium averaged 5.006 ± 1.30 billion / g before taking the medicine and rose to 18.73 ± 1.43 billion / g 10.7 days after taking medicine, increasing 370 times (P <005) Significant difference. Lactobacillus before taking the average number of 2  74 ± 0  25 million / g, 10 days after taking to 5  07 ± 1  21 million / g, an increase of 1  85 times. While on aerobic E. coli and other enterococci have a sustained inhibition of E. coli before taking an average of 342 ± 021 million / g, 10 days after taking to 1  105 ± 0  90 million / G, only 30% of the original (P <0  05), there are significant differences